arrow
M

Matteo Lambertini

University of Genova
H指数:66
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antibiotic Exposure and Treatment Outcomes in Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

抗生素暴露与头颈鳞状细胞癌和鼻咽癌的治疗结局:一项系统评价和Meta分析

2026-11-070
PRE
Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer

BRCA1和BRCA2致病性变异的类型和基因组位置在遗传性乳腺癌和卵巢癌中的临床意义

2026-09-290
OAAI
Effect of dose-dense adjuvant chemotherapy in patients with node-positive early breast cancer according to estrogen receptor levels: an exploratory analysis of the GIM2 trial

根据雌激素受体水平,剂量密集型辅助化疗对淋巴结阳性早期乳腺癌患者的影响:GIM2试验的探索性分析

Breast
IF7.9
2026-09-290
OA
Advancing breast cancer clinical management through technological innovation: the potential role of artificial intelligence and integrated care models

通过技术创新推动乳腺癌临床管理:人工智能和整合护理模式的潜在作用

2026-08-010
OAAI
Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy

磷酸酶和张力蛋白同源物状态对接受二线治疗的复发性IDH野生型胶质母细胞瘤的预后影响

2026-07-270
OA
Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]

人表皮生长因子受体2(HER2)阳性乳腺癌患者中的术后放疗:辅助拉帕替尼和/或曲妥珠胺治疗优化(ALTTO)试验(BIG 2-06/NCCTG N063D(Alliance))的回顾性探索性队列分析

2026-07-010
PRE
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
2026-06-240
OAAI
De-Escalated Chemotherapy and Endocrine Therapy Outcomes in Young Women with Stage I HR+/HER2+ Breast Cancer: An International Real-World Study.

在年轻女性中,针对I期HR+/HER2+乳腺癌的降级化疗和内分泌治疗效果:一项国际真实世界研究。

2026-06-110
OAAI
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: a systematic literature review of real-world evidence

曲拉曲坦在HER2阳性晚期/转移性乳腺癌患者中的应用:一项真实世界证据的系统文献综述

2026-06-090
OAAI
Efficacy of Alectinib for ALK-positive NSCLC According to Tumor Burden and Body Mass Index: a Pooled Analysis of the Randomized Phase III Trials ALEX and J-ALEX

根据肿瘤负荷和体重指数评估阿来替尼对ALK阳性NSCLC的疗效:ALEX和J-ALEX随机III期试验的合并分析

2026-06-050
OAAI
Real-world Effectiveness of CDK4/6 Inhibitors in Older Patients with HR+/HER2- Advanced Breast Cancer: a sub-analysis of the multicenter, PALMARES-2 study

CDK4/6抑制剂在HR+/HER2-晚期乳腺癌老年患者中的真实世界有效性:一项多中心PALMARES-2研究的子分析

2026-06-010
OAAI
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+breast cancer: An international real-world study.

年轻女性中I期HR+/HER2+乳腺癌降级化疗和内分泌治疗效果:一项国际真实世界研究

2026-06-010
PRE
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial

HER2低表达乳腺癌的密集剂量辅助化疗:GIM2试验的探索性分析

Breast
IF7.9
2026-06-010
OA
World Health Organization classification of tumours of the breast 6th edition 2026

世界卫生组织乳腺肿瘤分类第六版2026

2026-04-210
OAAI